Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 16.17 USD 1.63% Market Closed
Market Cap: 2.5B USD

Adaptive Biotechnologies Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Adaptive Biotechnologies Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Operating Income
-$78.4m
CAGR 3-Years
29%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Operating Income
$8B
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Operating Income
$4.7B
CAGR 3-Years
-14%
CAGR 5-Years
6%
CAGR 10-Years
7%
Mettler-Toledo International Inc
NYSE:MTD
Operating Income
$1.1B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Operating Income
$1.5B
CAGR 3-Years
-3%
CAGR 5-Years
12%
CAGR 10-Years
11%
IQVIA Holdings Inc
NYSE:IQV
Operating Income
$2.3B
CAGR 3-Years
6%
CAGR 5-Years
27%
CAGR 10-Years
13%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
9.3 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Operating Income?
Operating Income
-78.4m USD

Based on the financial report for Sep 30, 2025, Adaptive Biotechnologies Corp's Operating Income amounts to -78.4m USD.

What is Adaptive Biotechnologies Corp's Operating Income growth rate?
Operating Income CAGR 5Y
10%

Over the last year, the Operating Income growth was 53%. The average annual Operating Income growth rates for Adaptive Biotechnologies Corp have been 29% over the past three years , 10% over the past five years .

Back to Top